Evidence map›Paper›PMID 38091086›Full record

ArticleJournal of neurology2024

Peering further into the mind's eye: combining visual evoked potential and optical coherence tomography measures enhances insight into the variance in cognitive functioning in multiple sclerosis.

Thomas J Covey, Daniel Golan, Robert Sergott, Jeffrey Wilken, Myassar Zarif, Barbara Bumstead, MariJean Buhse, Olivia Kaczmarek, Glen M Doniger, Iris-Katharina Penner and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 11 institutions in 5 countries.

Thomas J CoveyDivision of Cognitive and Behavioral Neurosciences, Department of Neurology, Neuroscience Program, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Sherman Hall Annex 114, Buffalo, NY, USA. tjcovey@buffalo.edu.ORCID http://orcid.org/0000-0001-5183-3887
Daniel GolanMultiple Sclerosis and Neuroimmunology Center, Clalit Health Services, Nazareth, Israel.
Robert SergottWills Eye Institute and the William H. Annesley EyeBrain Center, Thomas Jefferson University, Philadelphia, PA, USA.
Jeffrey WilkenWashington Neuropsychology Research Group, Fairfax, VA, USA.
Myassar ZarifSouth Shore Neurologic Associates, New York University, Patchogue, New York, NY, USA.
Barbara BumsteadSouth Shore Neurologic Associates, New York University, Patchogue, New York, NY, USA.
MariJean BuhseSouth Shore Neurologic Associates, New York University, Patchogue, New York, NY, USA.
Olivia KaczmarekSouth Shore Neurologic Associates, New York University, Patchogue, New York, NY, USA.
Glen M DonigerDepartment of Clinical Research, NeuroTrax Corporation, Modiin, Israel.
Iris-Katharina PennerDepartment of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Laura M HancockDepartment of Neurology, University of Wisconsin School of Medicine, Madison, WI, USA.
Hans BogaardtSchool of Allied Health Science and Practice, University of Adelaide, Adelaide, Australia.
Marissa A BarreraKatz School of Science and Health, Yeshiva University, New York, NY, USA.
Sarah A MorrowLondon Health Sciences Centre, University of Western Ontario, Ontario, ON, Canada.
Steve GalettaDepartment of Neurology, New York University, New York, NY, USA.
Mark GudesblattSouth Shore Neurologic Associates, New York University, Patchogue, New York, NY, USA. mark.gudesblatt@nyulangone.org.
Urology Associates · USGeorgetown University · USJacobs Institute · USNew York University · USTechnion – Israel Institute of Technology · ILThe University of Adelaide · AUThomas Jefferson University · USUniversity of Bern · CHUniversity of Wisconsin–Madison · USWestern University · CAYeshiva University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSpectral Optical Coherence Tomography (OCT) and Visual Evoked Potentials (VEPs) have both emerged as potentially useful biomarkers of cognitive decline in people with multiple sclerosis (PwMS). Their combined use may provide additional predictive value for identifying disease impact, progression, and remyelination capacity above-and-beyond what is captured using either approach alone.

objectiveWe examined the relationship between OCT/VEP measures and cognitive functioning in 205 PwMS. OCT measures included Retinal Nerve Fiber Layer Volume (RNFLV), Papillo-Macular Bundle Volume (PBMV), and Macular Volume (MV). VEP measures included latency of the P100, and inter-ocular latency. Cognitive performance was evaluated across seven separate domains of performance, and for overall cognition, using the NeuroTrax computerized testing battery.

resultsBoth OCT and VEP measures were significantly correlated with cognitive performance across several domains. Linear regression models that controlled for the influence of visual acuity revealed (1) that reduced MV was significantly predictive of poorer visual-spatial functioning, and (2) that delayed VEP latency was significantly predictive of performance in global cognitive functioning and visual-spatial functioning, after controlling for multiple comparisons. Among PwMS with normal visual acuity, PwMS with a combination of both relatively low MV and delayed VEP latency tended to have poorer performance in the domains of global, executive, and visual-spatial functioning compared to PwMS with both high MV and normal VEP latency.

conclusionApproaches that combine the use of OCT and VEP measures can enhance insight into underlying factors that contribute to variance in cognitive functioning in PwMS.

Indexed as

Multiple SclerosisCognitionEvoked Potentials, VisualHumansRetinaTomography, Optical CoherenceCognitive functioningMacular volumeOccipital coherence tomographyP100Visual evoked potentials

Identifiers

PMID38091086
OpenAlexW4389682341

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.